Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 4.44
(4.72%)
SEK 4.44
(4.72%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.39 Million SEK | 15.97% |
| 2022 | -19.51 Million SEK | -48.72% |
| 2021 | -13.12 Million SEK | -365.68% |
| 2020 | -2.81 Million SEK | -1399.77% |
| 2019 | -187.87 Thousand SEK | -5229.82% |
| 2018 | -3525.00 SEK | 28.9% |
| 2017 | -4958.00 SEK | -2.8% |
| 2016 | -4823.00 SEK | -101.13% |
| 2015 | 427.84 Thousand SEK | -5.8% |
| 2014 | 454.17 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.36 Million SEK | -13.06% |
| 2024 Q2 | -5.62 Million SEK | -4.71% |
| 2023 Q4 | -4.74 Million SEK | 5.89% |
| 2023 Q3 | -5.04 Million SEK | -16.39% |
| 2023 FY | -16.39 Million SEK | 15.97% |
| 2023 Q1 | -2.26 Million SEK | 41.04% |
| 2023 Q2 | -4.33 Million SEK | -91.28% |
| 2022 Q2 | -3.69 Million SEK | 22.56% |
| 2022 Q1 | -4.76 Million SEK | -122.58% |
| 2022 FY | -19.51 Million SEK | -48.72% |
| 2022 Q4 | -3.84 Million SEK | 46.66% |
| 2022 Q3 | -7.2 Million SEK | -95.22% |
| 2021 Q3 | -6.75 Million SEK | -271.31% |
| 2021 Q2 | -1.81 Million SEK | 24.39% |
| 2021 FY | -13.12 Million SEK | -365.68% |
| 2021 Q1 | -2.4 Million SEK | 7.36% |
| 2021 Q4 | -2.14 Million SEK | 68.28% |
| 2020 Q1 | -4900.00 SEK | 0.0% |
| 2020 FY | -2.81 Million SEK | -1399.77% |
| 2020 Q4 | -2.59 Million SEK | -1129.81% |
| 2020 Q3 | -211.13 Thousand SEK | -1897.46% |
| 2020 Q2 | -10.57 Thousand SEK | -115.71% |
| 2019 FY | -187.87 Thousand SEK | -5229.82% |
| 2018 FY | -3525.00 SEK | 28.9% |
| 2017 FY | -4958.00 SEK | -2.8% |
| 2016 FY | -4823.00 SEK | -101.13% |
| 2015 FY | 427.84 Thousand SEK | -5.8% |
| 2014 FY | 454.17 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 64.197% |
| Biovica International AB (publ) | -124.82 Million SEK | 86.863% |
| Cantargia AB (publ) | -280.02 Million SEK | 94.144% |
| CombiGene AB (publ) | -35.66 Million SEK | 54.023% |
| Cyxone AB (publ) | -22.98 Million SEK | 28.67% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -40.418% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 82.059% |
| Fluicell AB (publ) | -26.55 Million SEK | 38.247% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 86.676% |
| Mendus AB (publ) | -101.61 Million SEK | 83.863% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 55.766% |
| I-Tech AB | 20.2 Million SEK | 181.166% |
| Intervacc AB (publ) | -102.85 Million SEK | 84.057% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -35.208% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 234.752% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 8.376% |
| OncoZenge AB (publ) | -15.9 Million SEK | -3.119% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -3643.83% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 95.776% |
| Lipum AB (publ) | -37.17 Million SEK | 55.893% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 93.403% |
| Ziccum AB (publ) | -21.41 Million SEK | 23.417% |
| BioArctic AB (publ) | 229.24 Million SEK | 107.153% |
| Genovis AB (publ.) | 61.5 Million SEK | 126.663% |
| Camurus AB (publ) | 431.44 Million SEK | 103.801% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 90.779% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 71.141% |
| Aptahem AB (publ) | -11.11 Million SEK | -47.558% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 94.726% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 90.873% |
| Kancera AB (publ) | -64.88 Million SEK | 74.729% |
| Saniona AB (publ) | -95.81 Million SEK | 82.885% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 61.163% |
| AcouSort AB (publ) | -17.08 Million SEK | 4.044% |
| Xintela AB (publ) | -54.08 Million SEK | 69.68% |
| Abliva AB (publ) | -95.5 Million SEK | 82.831% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 404.456% |
| Amniotics AB (publ) | -30.87 Million SEK | 46.881% |
| 2cureX AB (publ) | -32.51 Million SEK | 49.573% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -27.83% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 96.483% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 98.028% |
| Biosergen AB | -27.03 Million SEK | 39.35% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 0.757% |
| Corline Biomedical AB | -1.8 Million SEK | -806.466% |
| NextCell Pharma AB | -41.95 Million SEK | 60.92% |
| Nanologica AB (publ) | -75.15 Million SEK | 78.182% |
| LIDDS AB (publ) | -40.2 Million SEK | 59.215% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 94.984% |
| BioInvent International AB (publ) | -330.3 Million SEK | 95.035% |
| SynAct Pharma AB | -215.81 Million SEK | 92.402% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 62.778% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 30.918% |
| Alzinova AB (publ) | -16.48 Million SEK | 0.498% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 84.996% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 93.417% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -65.136% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 85.53% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 22.251% |
| Simris Alg AB (publ) | -37.3 Million SEK | 56.043% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 89.201% |